Cytokinetics (CYTK) announced that the European Medicines Agency, EMA, has validated the Marketing Authorization Application, MAA, for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy, HCM. The MAA will now be reviewed by the Committee for Medicinal Products for Human Use, CHMP. “With regulatory filings for aficamten already under review in both the U.S. and China, the validation of the MAA marks an important milestone in bringing this potential medicine to even more patients with HCM worldwide,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We look forward to working with EMA in connection with their review of our application.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Sanofi to acquire rights to develop, commercialize aficamten from Corxel
- Cytokinetics price target raised to $82 from $80 at RBC Capital
- Cytokinetics opens enrollment for COMET-HF Phase 3 trial
- Cytokinetics announces FDA acceptance of NDA for aficamten
- Cytokinetics price target raised to $103 from $99 at Mizuho